ESMO 2023 | Novel treatment options for HER2-low breast cancer

Eva Ciruelos • 23 Oct 2023

Breast Cancer Antibodies Trastuzumab deruxtecan

DESTINY-Breast04 Immuno-Oncology

Eva Ciruelos, MD, PhD, University Hospital October 12, Madrid, Spain, comments on the latest therapeutic modalities for HER2-low breast cancer. Trastuzumab deruxtecan, a HER2-directed antibody-drug conjugate, has shown very promising results in the Phase III DESTINY-Breast04 trial (NCT03734029). This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Unmet needs in the use of CDK4/6 inhibitors in early-stage HR+/HER2- breast cancer

Eva Ciruelos • 16 Mar 2023

Updates in metastatic triple-negative breast cancer at ESMO 2023

Eva Ciruelos • 23 Oct 2023

Hot topics at St Gallen BCC

Eva Ciruelos • 16 Mar 2023

Unmet needs and CDK4/6 inhibitors in HR+/HER2- early breast cancer

Eva Ciruelos • 16 Mar 2023

Related Videos

IMpassion130 study: improvement in OS and PFS for IIT and PD-L1+ populations with mTNBC

Peter Schmid • 21 Oct 2018

What impact will biosimilars have on clinical life?

Diana Lüftner • 21 Sep 2017

Drug shortages around the world: why communication is key

Fatima Cardoso • 22 Sep 2017

HER-2 conversion: a phenomenon in trastuzumab resistance

Russell Petty • 5 Nov 2019